ANO1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1896076	0.70	20/20
SCHEMBL1795098	0.64	20/20
SCHEMBL1895995	0.64	20/20
SCHEMBL1892978	0.61	20/20
SCHEMBL1895200	0.61	20/20
SCHEMBL1895227	0.60	20/20
SCHEMBL1893156	0.58	20/20
SCHEMBL1892497	0.58	20/20
SCHEMBL347250	0.53	20/20
SCHEMBL1896192	0.71	19/20
SCHEMBL1490464	0.68	19/20
SCHEMBL1891234	0.67	19/20
SCHEMBL1490332	0.66	19/20
SCHEMBL1893645	0.66	19/20
SCHEMBL1895277	0.63	19/20
SCHEMBL1895895	0.61	19/20
SCHEMBL1894667	0.60	19/20
SCHEMBL1896174	0.66	18/20
SCHEMBL1894867	0.63	18/20
SCHEMBL1895978	0.63	18/20

Clinical trials — most relevant to ANO1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1	PHASE3	ACTIVE_NOT_RECRUITING
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy	PHASE2	RECRUITING
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.	PHASE2	NOT_YET_RECRUITING
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
3 Year Follow up on ANO5 Patients	nan	ACTIVE_NOT_RECRUITING
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Families' Experiences of Paediatric ICC Diagnosis	nan	UNKNOWN
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Feasibility of Improving Risk Stratification in Brugada Syndrome	nan	COMPLETED
The Role of Biomarkers in Inherited Cardiac Conditions	nan	WITHDRAWN
Multidisciplinary Study of Right Ventricular Dysplasia	nan	COMPLETED
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia	nan	COMPLETED
The Genetic Basis of Atrial Fibrillation (AF)	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Determinants of Cardiorespiratory Fitness and Effects of HIIT in Patients With ANOCA Obstructive Coronary Artery Disease(ANOCA)	nan	RECRUITING
Precision Medicine for Nociception, Sngception and Proprioception.	nan	RECRUITING
Heart and Skeletal Muscle Problems in Neuroacanthocytosis	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Piezo2-related Arthrogryposis & physiopathOLOgy 3	nan	NOT_YET_RECRUITING
Early PKD Observational Cohort Study	nan	RECRUITING
Evaluation of Serum Tumor Endothelial Marker1 as a Potential Biomarker for Colorectal Cancer Diagnosis and Cancer Progression	nan	NOT_YET_RECRUITING
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis	nan	UNKNOWN
Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders	nan	RECRUITING
Role of TMEM219 Marker in Type 1 Diabetes	nan	UNKNOWN
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ANO1 binder may also engage these)

Protein	Name	Similarity
Q8BHY3	—	1.000	Q8BHY3 →
Q8CFW1	—	0.995	Q8CFW1 →
Q5YCC7	—	0.995	Q5YCC7 →
Q75V66	—	0.995	Q75V66 →
Q6P9J9	—	0.994	Q6P9J9 →
Q75UR0	—	0.994	Q75UR0 →
ANO2	Anoctamin-2	0.992	landscape →
P19334	—	0.992	P19334 →
Q61056	—	0.991	Q61056 →
Q4KMQ2	—	0.991	Q4KMQ2 →
P51914	—	0.991	P51914 →
Q17529	—	0.990	Q17529 →
Q93380	—	0.989	Q93380 →
O18304	—	0.989	O18304 →
Q7TQ69	—	0.988	Q7TQ69 →
Q7Z5M5	—	0.988	Q7Z5M5 →
O62852	—	0.988	O62852 →
Q18695	—	0.987	Q18695 →
Q11069	—	0.987	Q11069 →
Q0JJZ6	—	0.987	Q0JJZ6 →
P36380	—	0.987	P36380 →
Q6IWH7	—	0.987	Q6IWH7 →
A2YD22	—	0.986	A2YD22 →
Q0V990	—	0.986	Q0V990 →
P28231	—	0.986	P28231 →
Q6IFT6	—	0.986	Q6IFT6 →
Q9QUQ5	—	0.986	Q9QUQ5 →
TRPC1	Short transient receptor potential channel 1	0.986	landscape →
A0MFS9	—	0.986	A0MFS9 →
Q7T047	—	0.985	Q7T047 →